Response to the letter to the editor entitled 'Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic'

Expert Rev Cardiovasc Ther. 2021 Feb;19(2):189-190. doi: 10.1080/14779072.2021.1862548. Epub 2020 Dec 15.

Authors

Leonardo Grabinski Bottino¹, Flávio Danni Fuchs^{1

2}

Affiliations

¹ Post-graduate Program in Cardiovascular Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul Porto Alegre.
² Division of Cardiology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil.

PMID: 33297777
DOI: 10.1080/14779072.2021.1862548

No abstract available

Publication types

Letter
Comment

MeSH terms

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Angiotensins
Antihypertensive Agents / therapeutic use
COVID-19*
Humans
Hypertension* / drug therapy
Hypertension* / epidemiology
Pandemics
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins
Antihypertensive Agents